Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janaki Amin

Showing results (51-60 of 196) with videos related to

Pageof 20
Sort By:
Plos One|April 12, 2014
Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudineHila Haskelberg, Nicholas Pocock, Janaki Amin, et al.
Plos One|November 3, 2011
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudineAllison Martin, Janaki Amin, Sean Emery, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 22, 2009
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trialAllison Martin, Mark Bloch, Janaki Amin, et al.
Vaccine|July 31, 2023
Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infectionBette Liu, Sandrine Stepien, Jiahui Qian, et al.
HIV Clinical Trials|May 29, 2002
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 studyMartyn French, Janaki Amin, Norman Roth, et al.
Journal of Hepatology|July 13, 2016
Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based studyMaryam Alavi, Matthew G Law, Jason Grebely, et al.
International Journal of Environmental Research and Public Health|July 2, 2021
What Is the Evidence Globally for Culturally Safe Strategies to Improve Breast Cancer Outcomes for Indigenous Women in High Income Countries? A Systematic ReviewVita Christie, Debbie Green, Janaki Amin, et al.
Plos One|June 22, 2012
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudineHila Haskelberg, Jennifer F Hoy, Janaki Amin, et al.
AIDS Research and Treatment|June 8, 2012
Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australiaAmit C Achhra, Janaki Amin, Jennifer Hoy, et al.
Journal of Hepatology|August 14, 2017
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regressionReem Waziry, Behzad Hajarizadeh, Jason Grebely, et al.
Pageof 20

Showing results (51-60 of 196) with videos related to

Sort By:
Pageof 20
Plos One|April 12, 2014
Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudineHila Haskelberg, Nicholas Pocock, Janaki Amin, et al.
Plos One|November 3, 2011
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudineAllison Martin, Janaki Amin, Sean Emery, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 22, 2009
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trialAllison Martin, Mark Bloch, Janaki Amin, et al.
Vaccine|July 31, 2023
Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infectionBette Liu, Sandrine Stepien, Jiahui Qian, et al.
HIV Clinical Trials|May 29, 2002
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 studyMartyn French, Janaki Amin, Norman Roth, et al.
Journal of Hepatology|July 13, 2016
Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: A population-based studyMaryam Alavi, Matthew G Law, Jason Grebely, et al.
International Journal of Environmental Research and Public Health|July 2, 2021
What Is the Evidence Globally for Culturally Safe Strategies to Improve Breast Cancer Outcomes for Indigenous Women in High Income Countries? A Systematic ReviewVita Christie, Debbie Green, Janaki Amin, et al.
Plos One|June 22, 2012
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudineHila Haskelberg, Jennifer F Hoy, Janaki Amin, et al.
AIDS Research and Treatment|June 8, 2012
Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australiaAmit C Achhra, Janaki Amin, Jennifer Hoy, et al.
Journal of Hepatology|August 14, 2017
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regressionReem Waziry, Behzad Hajarizadeh, Jason Grebely, et al.
Pageof 20